Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD
David Henry MD Advisory Board
Roger Stupp MD
Roger Stupp MD Advisory Board
Roxana Dronca MD
Roxana S. Dronca MD Advisory Board
See All Experts
featured
Published in Oncology

Expert Opinion / Commentary · November 06, 2017

2017 Top Stories in Oncology: IDEA—Duration of Adjuvant Therapy in Stage III Colon Cancer

Jeffrey Kirshner MD, FACP, FASCO

 

 Save  Recommend
 Share

Additional Info

  1. Shi Q, Sobrero AF, Shields AF, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA1.

Further Reading

Most Read This Week

Recently Updated